Aurinia Pharmaceuticals IncEducation
Achieving Highest Complete Remission Rate of Any Lupus study
- Low dose voclosporin achieves CR rate of 49.4% at 48 weeks (p<.001)
- AURORA Phase III trial with low dose voclosporin on track to commence in Q2 2017
ir.auriniapharma.com/press-releases/detail/73
seekingalpha.com/article/4051484-aurinia-successful-48-week-phase-2b-trial-results-even-better-expected
- AURORA Phase III trial with low dose voclosporin on track to commence in Q2 2017
ir.auriniapharma.com/press-releases/detail/73
seekingalpha.com/article/4051484-aurinia-successful-48-week-phase-2b-trial-results-even-better-expected
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.